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IN THE LATE 1970S, A SURGEON IN 
Melbourne, Australia, wanted to fi gure out 
why his country had a relatively high rate of 
colorectal cancer. After he and colleagues 
interviewed more than 700 cancer patients 
and a comparable number of healthy people, 
they reported in 1987 and 1988 that Austra-
lians’ penchant for beer, fatty foods, and red 
meat all seemed to predispose them to 
the disease. The researchers also found a 
surprising protective factor: People who 
regularly used aspirin were 40% less 
likely to develop colorectal cancer than 
those who didn’t take the drug.
That fi rst hint that the age-old head-
ache remedy also blocks intestinal 
tumors helped spur a wave of research 
in animals and clinical trials that estab-
lished that aspirin and other nonsteroidal 
anti-inflammatory drugs (NSAIDs) 
protect against colon cancer. And now, 
2 decades later, aspirin is generating new 
excitement among cancer researchers. A 
series of studies from the United King-
dom in the last 2 years has offered the 
fi rst evidence from placebo-controlled 
clinical trials that regularly taking low 
doses of aspirin wards off other types of 
cancer as well. 
The studies, which tallied cancer 
cases among people who had been tak-
ing aspirin for years to prevent vascular 
events such as heart attack and stroke, 
found that death rates from several 
tumor types were as much as 37% lower. 
And even in the people who developed 
a cancer, taking aspirin seemed to slow 
the spread of tumors to other parts of the 
body. “It’s just about the fi rst proof of prin-
ciple that a simple compound of any kind can 
reduce the risk of several cancers,” says lead 
researcher Peter Rothwell of the University 
of Oxford in the United Kingdom.
These reports have raised the tantaliz-
ing possibility that aspirin could serve as 
the fi rst anticancer drug for the general pop-
ulation. “It reshapes the debate about the 
risks and benefi ts of aspirin for cancer pre-
vention,” says colorectal cancer researcher 
Andrew Chan of Massachusetts General 
Hospital in Boston. 
Because aspirin can cause stomach upset 
and dangerous internal bleeding, U.S. guide-
lines now recommend that only people at 
elevated risk for heart disease or stroke take 
low doses of the medicine, typically 81 milli-
grams a day. But Chan and others suggest that 
medical societies and policymakers should 
also consider aspirin’s general cancer-fi ghting 
effects. Rothwell, who is 48, is so convinced 
by his team’s data, for example, that he’s 
begun taking aspirin daily even though he has 
no risk factors for vascular disease.
The new British aspirin studies are also 
fueling basic research on NSAIDs to ward 
off cancer, a field that lost momentum in 
the past decade when one NSAID, Vioxx, 
was pulled off the market because of safety 
concerns. Partly because of the U.K. results, 
U.S. National Cancer Institute (NCI) Direc-
tor Harold Varmus last year added to his list 
of 24 “Provocative Questions” one that asks 
what is the mechanism by which aspirin and 
other NSAIDs protect against cancer (see 
sidebar, p. 1472). NCI hopes the attempt to 
resolve the question—there are several com-
peting theories—will lead to next-generation 
anticancer drugs and biomarkers showing 
who will respond to them.
But some cancer researchers say health 
policymakers needn’t wait for a better aspirin 
and should advocate wider use of the current 
one. “This is a really extraordinary oppor-
tunity if everything bears out, because you 
have a drug that costs a penny a pill at a low 
dose, that can prevent the two major causes of 
death in the Western world,” says epidemiol-
ogist Michael Thun of the American Cancer 
Society in Atlanta.
Comeback
Thun’s optimism is the latest high in the 
up-and-down story of NSAIDs as a can-
cer preventive. Aspirin and some other 
NSAIDs fi rst bore out their promise in 
trials published starting in 2000 among 
people who had had precancerous colon 
polyps removed and others genetically 
prone to colorectal cancer. The drugs 
protected them from polyps and prema-
lignant tumors that precede full-blown 
cancer. Such people are now sometimes 
advised by their doctors to take NSAIDs 
as an adjunct to surgery to prevent pol-
yps from recurring. 
Although epidemiological evidence 
has suggested that aspirin could have 
broader anticancer effects, those results 
aren’t conclusive. They come from stud-
ies in which people answered questions 
about their past use of medications—
a design prone to bias in part because 
memories aren’t reliable. And hopes 
for aspirin fell in 2005 when a huge 
prospective study—a randomized con-
trolled trial called the Women’s Health 
Study (WHS)—failed to show a reduc-
tion in the incidence of cancer in nearly 
40,000 women who took low-dose aspirin 
every other day for 10 years. 
The fi eld of NSAIDs for cancer preven-
tion also suffered a black eye when two arthri-
tis drugs developed to avoid the side effects 
of aspirin, the COX-2 inhibitors Vioxx and 
Celebrex, were tested in trials to prevent 
colon polyps. In one large trial, Vioxx cut the 
risk of polyps but raised the chances of heart 
attack so much that risk arguably outweighed 
the cancer benefi t. Vioxx was pulled off the 
market in 2004 and Celebrex, although still 
used for preventing colorectal cancer in peo-
ple at high risk of such disease, now carries a 
Will an Aspirin a Day Keep 
Cancer Away?
Data suggesting that regular aspirin use lowers cancer risk has accumulated to the point 
where some argue that it’s time to recommend that many more people take the drug



















































































“black box” warning label. 
The pendulum began to swing back in 
favor of aspirin, however, when Rothwell, a 
neurologist, noticed that fewer overall can-
cers had occurred among patients in the 
treatment arm of randomized trials launched 
in the 1980s to test aspirin as a way to pre-
vent stroke. Amassing details on the can-
cers from patients’ paper health records and 
U.K. health databases, his team initially con-
fi rmed aspirin’s ability to ward off colorec-
tal cancers, reporting in 2007 that there were 
24% fewer cases and 35% fewer deaths in 
the aspirin group after several years. Then 
in late 2010, they reported that patients 
taking aspirin at any dose daily for at least 
5 years cut by 21% the long-term risk of 
dying from colorectal, gastrointestinal, 
esophageal, stomach, pancreatic, brain, 
lung, and prostate cancers.
Rothwell’s group expanded on these 
results in three papers published in The 
Lancet and The Lancet Oncology this 
spring. One, a meta-analysis of 51 random-
ized trials in which aspirin was taken daily, 
found 37% fewer deaths from cancers after 
5 years. (The study came 
with a large caveat: It 
excluded WHS and an ear-
lier trial that found no ben-
efi t, the Physicians’ Health 
Study, because participants 
in each took aspirin only every other day.) 
This meta-analysis also found that while 
the aspirin group had more stomach bleeds, 
these incidents were not fatal—people 
recovered—and the bleeding risk went down 
after several years on aspirin. Another paper 
found that people on aspirin who developed 
cancer were 36% less likely to have tumors 
that had spread. A third paper found a 
“remarkable consistency” in the drop in can-
cers among aspirin users in epidemiologic 
studies and clinical trials, Rothwell says.
While these studies weren’t designed spe-
cifi cally to test aspirin against cancer, some 
researchers say that because so many people 
now take aspirin off-label it would be diffi -
cult to conduct better tri-
als. The Rothwell studies 
are “probably the best evi-
dence we’ll ever have on this 
topic,” Chan says.
Weighing risks
Chan is part of an interna-
tional panel on cancer pre-
vention that, in response 
to the Rothwell studies, plans to update its 
stance on aspirin published 3 years ago. 
The group’s leader, epidemiologist Jack 
Cuzick of Queen Mary, University of Lon-
don expects the panel may suggest that 
people take low doses of aspirin daily start-
ing around age 50 and stopping by age 70, 
when the risk of internal bleeding rises. The 
group may also discuss whether doctors 
should screen patients for the ulcer-causing 
Helicobacter pylori bacterium, treating 
those who test positive with antibiotics 
before putting them on aspirin, to reduce 
the risk of bleeds. 
Some U.S. researchers also suggest that 
it’s time for the U.S. Preventive Services 
Wondering How the Wonder Drug Works
Believer. Peter Rothwell’s can-
cer studies convinced him to 
take a daily aspirin.
HOW DOES TAKING ASPIRIN WARD OFF CANCER? RESEARCHERS 
still don’t understand the mechanism, a lack of knowledge that threat-
ens to frustrate development of better cancer prevention agents. 
But some say the latest clinical studies linking low-dose aspirin use 
with less cancer (see main story, p. 1471) suggest there’s no need to 
improve upon this 113-year-old workhorse drug.
Among its many known effects, aspirin, or acetylsalicylic acid, 
inhibits two forms of enzymes known as cyclooxygenases (COX) that 
convert arachidonic acid into lipids called prostaglandins. Prosta-
glandins made by COX-1 protect the stomach lining, while those made 
by COX-2 are involved in infl ammation. Aspirin’s inhibitor effects 
on COX-1 seem to explain why the medicine can upset stom-
achs and trigger internal bleeding. Many researchers have 
concluded that aspirin prevents cancer mainly by blocking 
the activity of COX-2. That’s because the same infl amma-
tion-driven responses that help tissue recovery from wound 
injury—cell division, blood vessel formation, and suppression 
of programmed cell death, for example—may also help tumors grow.
Several lines of evidence implicate COX-2 in cancer induction. 
The enzyme is overproduced in many cancer types; mice lacking 
its gene are less prone to colon cancer; and trials of nonsteroidal 
anti-infl ammatory drugs (NSAIDs) that target only COX-2 protected 
against precancerous colon polyps in people at high risk. 
Reducing infl ammation via COX-2 probably isn’t the only way aspi-
rin prevents cancer, however. “We are as a fi eld getting down to some 
of the mechanisms, but it’s very complicated,” says Raymond Dubois 
of the MD Anderson Cancer Center in Houston, Texas. A decade ago, 
researchers found that aspirin can block production of a protein called 
NF-κB that protects cells from early death. Although the studies were 
done in the test tube at aspirin doses much higher than those in the 
bloodstream, the NF-κB hypothesis remains on the table—along with 
more than a dozen possible mechanisms—from inhibiting various cell 
growth pathways to targeting cancer stem cells. “There are a number 
of very different, divergent ideas,” says Asad Umar of the National Can-
cer Institute’s Division of Cancer Prevention in Bethesda, Maryland.
Some experts say new clinical studies of low-dose aspirin and can-
cer suggest that COX-2 isn’t directly involved at all. That’s because at 
low doses, the drug doesn’t block COX-2 but still impairs platelets, the 
small cell fragments in blood that help form clots, via the COX-1 path-
way. Studies suggest that platelets blunt the immune attack on cancer 
cells traveling in blood and produce growth factors that help them take 
root in a new place, notes University of Pennsylvania pharmacologist 
Garrett FitzGerald. Some experiments suggest that activated platelets 
can also stimulate the COX-2 pathway in adjacent cells, which would 
explain how aspirin, by damping COX-2 at the site of an injury, could 
block the early stages of colorectal cancer, says Carlo Patrono, a phar-
macologist at the Catholic University in Rome, Italy. 
Efforts to make an alternative to standard aspirin haven’t yet panned 
out. Several drugs that target only COX-2, notably Vioxx and Celebrex, 
unacceptably raised heart attack risk, for example. And a version of 
acetylsalicylic acid containing a chemical group called nitric oxide that 
was supposed to reduce side effects failed to gain regulatory approval. 
Some researchers are combining aspirin with other compounds such 
as a lipid to reduce stomach upset. But these are years from the clinic. 
For now, “I don’t think a better aspirin is the issue,” but rather fi guring 































































































PHILADELPHIA, PENNSYLVANIA—The food 
market Clara Santos runs in South Philadel-
phia is less than 5 kilometers from the city’s 
majestic art museum. Driving there, polished 
brick townhouses and trendy eateries with 
names like Caffeination and The Belgian 
Café give way to stretches of modest row 
houses, abandoned lots, and the occasional 
corner store advertising massive sandwiches 
called hoagies. Santos, who emigrated from 
the Dominican Republic, lives not far from 
the Olivares Food Market she took over 
4 years ago. Graffi ti marks its outer walls, 
but the shop, on a quiet block sandwiched 
between two city schools, is tidy inside. Chil-
dren stop in frequently for soda and candy 
after classes let out.
Santos’s store is one of 642 data points in 
an unusual urban experiment. Eight years ago, 
a local nonprofi t called The Food Trust began 
studying whether bringing healthy, affordable 
food to corner stores like hers could change 
eating habits among the city’s economically 
disadvantaged residents. The program started 
small. Then in 2010, the Healthy Corner 
Store Initiative rapidly expanded after part-
nering with the Department of Public Health 
here, which had just received a windfall: 
$15 million to help prevent obesity, part of 
$373 million from the federal stimulus pack-
age earmarked for health and wellness efforts 
around the country. Santos joined the project 
last year along with hundreds of other con-
venience store owners. Among other support, 
she received a display refrigerator where she 
showcases yogurt, precut watermelon, car-
rots, apples, and other fruits and vegetables, 
along with green bins for produce such as 
onions and plantains. Why not give the pro-
gram a try, Santos says she thought: “Maybe 
we’ll help the community.”
Like Santos and those at The Food Trust, 
more and more people are trying to change 
the landscape of food in America. And change 
is desperately needed. More than one-third of 
Tackling America’s Eating Habits, One Store at a Time
Several initiatives are evaluating if easing access to healthy food will change how 
Americans eat—and reduce obesity around the country
Task Force (see p. 1468) to 
update its guidelines on the 
risks and benefits of daily 
aspirin use. The group had 
endorsed its preventive 
prowess for heart attack 
and stroke but discounted 
its anticancer effects. The 
potential to protect against 
both cancer and heart dis-
ease could tip the balance toward recom-
mending aspirin for many more healthy 
adults, Thun says. 
Others are more cautious about recom-
mending broad use of aspirin to ward off can-
cer. “In 2012, gastroenterol-
ogists still get called to the 
emergency room for bleeds” 
caused by the drug, says 
cancer prevention researcher 
Andrew Dannenberg of Cor-
nell University. Colorectal 
cancer researcher Sanford 
Markowitz of Case Western 
Reserve University in Cleve-
land, Ohio, points to studies suggesting that 
only people with a particular genetic profi le 
will see their cancer risk go down if they take 
aspirin. “I would want more data on who 
benefi ts and who does not,” Markowitz says. 
Cancer prevention researcher Raymond 
Dubois of the MD Anderson Cancer Cen-
ter in Houston, Texas, is also wary. “Ini-
tially we thought we could put aspirin in the 
drinking water. That’s not the case,” he says. 
“Where this fi eld is going is towards a more 
personalized approach.” 
The picture may become clearer soon 
when WHS reports on longer-term effects 
of aspirin on cancer risk. Their next paper 
“will be crucial,” Rothwell says. And even 
some on the pro-aspirin side urge cau-
tion. “We don’t want to mess this up,” 
Thun says. 
–JOCELYN KAISER
“ It reshapes the debate 
about the risk and 






With a push from a 
local nonprofi t, The 
Food Trust, and a 
windfall of federal 
funding, efforts are 
underway to boost 
healthy offerings at 
small grocers around 
the city.
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